@article{6e5d08a6561a400d9a976cb7dec0fd02,
title = "Current and future treatments for tuberculosis",
abstract = "Guidelines on the treatment of tuberculosis (TB) have essentially remained the same for the past 35 years, but are now starting to change. Ongoing clinical trials will hopefully transform the landscape for treatment of drug sensitive TB, drug resistant TB, and latent TB infection. Multiple trials are evaluating novel agents, repurposed agents, adjunctive host directed therapies, and novel treatment strategies that will increase the probability of success of future clinical trials. Guidelines for HIV-TB co-infection treatment continue to be updated and drug resistance testing has been revolutionized in recent years with the shift from phenotypic to genotypic testing and the concomitant increased speed of results. These coming changes are long overdue and are sorely needed to address the vast disparities in global TB incidence rates. TB is currently the leading cause of death globally from a single infectious agent, but the work of many researchers and the contributions of many patients in clinical trials will reduce the substantial global morbidity and mortality of the disease.",
author = "Anthony Lee and Xie, {Yingda Linda} and Barry, {Clifton E.} and Chen, {Ray Y.}",
note = "Funding Information: Acknowledgment: This research was supported by the Intramural Research Program of the US National Institutes of Health, National Institute of Allergy and Infectious Diseases. Contributorship: YLX, CEB, and RYC developed the idea for this review. AL, YLX, and RYC performed the literature search. AL, YLX, CEB, and RYC wrote the review. RYC is the guarantor. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. Funding Information: The international TB community jointly released DS-TB treatment guidelines in 2016.72 This effort was sponsored by the American Thoracic Society, the Centers for Disease Control and Prevention (CDC), and the Infectious Diseases Society of America and was endorsed by the European Respiratory Society and the US National Tuberculosis Controllers Association. The American Academy of Pediatrics, the Canadian Thoracic Society, the International Union Against Tuberculosis and Lung Disease, and WHO also participated. These guidelines note that treatment by directly observed therapy (DOT) by trained personnel compared with self-administered therapy (SAT) is the standard of care in most TB programs in the US and Europe. WHO released another version in 2017 with some updates primarily focused on patient care aspects.73The WHO guidelines allow for SAT but conditionally recommends either DOT in the community or home by trained providers or video observed therapy over SAT. For drug resistant TB, the primary guidelines are from WHO, which released its latest version in 2019.23 24 Recent reviews have been published for the management of drug resistant TB.74 75 Publisher Copyright: {\textcopyright} Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to.",
year = "2020",
month = mar,
day = "2",
doi = "10.1136/bmj.m216",
language = "English (US)",
volume = "368",
journal = "The BMJ",
issn = "0959-8146",
publisher = "BMJ Publishing Group",
}